Is Immunome, Inc. (IMNM) a Buy, Sell, or Hold?
Immunome, Inc.
NASDAQ:IMNM
$22.92 USD
$0.33 (1.46%)
- Volume
- 1.9M
- Average Volume
- 1.32M
- Market Capitalization
- $2.19B
- P/E Ratio
- -9.59
- Dividend Yield
- 0.00%
- Price Target
- $36.50
- Year High
- $27.65
- Year Low
- $8.48
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $21.68
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Clay Siegall |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | IMNM |
| CUSIP | 45257U108 |
| CIK | 0001472012 |
| Web | https://www.immunome.com |
| Phone | 610 321 3700 |
| Currency | USD |
| Employees | 177 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 21.68 |
| Quick Ratio | 21.68 |
| Cash Ratio | 21.26 |
Sales & Book Value
| Annual Sales | $6.94M |
| Price / Sales | 545.71 |
| Cash Flow | -1.82 |
| Price / Cash Flow | -10.66 |
| Price / Book | 4.40 |
Price Target and Rating
| Average Stock Price Forecast | $36.50 |
| High Stock Price Forecast | $40.00 |
| Low Stock Price Forecast | $33.00 |
| Forecast Upside/Downside | -37.21% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 13 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-2.43 |
| Trailing P/E Ratio | -9.59 |
| PEG Ratio | -0.34 |
| P/E Growth | -0.34 |
| Net Income | $-212.39M |
| Net Margin | -5593.85% |
| Pretax Margin | -5593.85% |
| Return on Equity | -51.15% |
| Return on Assets | -36.24% |
Financials Score
| AltmanZ Score | 40.18 |
| Piotroski Score | 2.00 |
| Working Capital | 566.9M |
| Total Assets | 619.79M |
| Ebit | -224.59M |
| Market Cap | 2.18B |
| Total Liabilities | 31.11M |
Poll Results
About Immunome, Inc. (NASDAQ:IMNM) Stock
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington. ...
What This Immunome Sale Means a Day Before a Big FDA Milestone
2026-07-12 16:44:53
An Immunome insider sold 100,000 shares for $2.4 million based on weighted average prices on July 6, 2026 and July 7, 2026. The transaction represents 32% of the insider's total equity holdings in the company.
Immunome Stock Up 32% in a Month: Here's What You Should Know
2026-07-10 11:41:06
IMNM jumps 32% in a month. This comes as the FDA accepts varegacestat's NDA for desmoid tumors, with an approval decision expected by April 2027.
2026-07-08 07:30:00
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted its New Drug Application (NDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-07 16:02:00
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on July 1, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 344,000 shares of common stock to seventeen new employees under the Company's 2024 In.
2026-06-11 08:00:00
[url="]Immunome, Inc.[/url] (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today a
2026-06-11 07:30:00
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-1617, a potential first-in-class ADC directed at an undisclosed solid tumor target and incorporating HC74, Immunome's proprietary TOP1 inhibitor payload. “The first patient dosed with IM-1617 is a significant milestone for Immunom.
2026-06-09 14:52:10
Immunome, Inc. (IMNM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Immunome: Varegacestat Is The Beachhead, But The ADC Engine Is The Thesis
2026-06-09 04:44:27
Immunome is evolving into a multi-asset targeted oncology platform, anchored by varegacestat's strong Phase 3 desmoid tumor data and an NDA submission. IMNM's cash position of $582.7M supports operations through 2028, enabling pipeline acceleration and mitigating near-term dilution risk. Varegacestat's efficacy (HR 0.16, ORR 56%) positions IMNM to challenge Ogsiveo in desmoid tumors, with broader TAM potential in ADCs and radioligand therapies.
Frequently Asked Questions
-
What is the current Immunome, Inc. (IMNM) stock price?
-
Immunome, Inc.(NASDAQ:IMNM) stock price is $22.92 in the last trading session. During the trading session, IMNM stock reached the peak price of $27.65 while $8.477 was the lowest point it dropped to. The percentage change in IMNM stock occurred in the recent session was 1.46% while the dollar amount for the price change in IMNM stock was $0.33.
-
IMNM's industry and sector of operation?
-
The NASDAQ listed IMNM is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of IMNM?
-
Robert J. Lechleider | Chief Medical Officer
Max Rosett | Chief Financial Officer
Sandra G. Stoneman | Chief Legal Officer, General Counsel & Corporate Secretary
Kinney Horn | Chief Business Officer
Clay Siegall | Chairman, President & Chief Executive Officer -
How many employees does IMNM have?
-
Number of IMNM employees currently stands at 177. IMNM operates from 18702 North Creek Parkway, Bothell, WA 98011, US.
-
Link for IMNM official website?
-
Official Website of IMNM is: https://www.immunome.com
-
How do I contact IMNM?
-
IMNM could be contacted at phone #610 321 3700 and can also be accessed through its website. IMNM operates from 18702 North Creek Parkway, Bothell, WA 98011, US.
-
How many shares of IMNM are traded daily?
-
The average number of IMNM shares traded daily for last 3 months was 1.32M.
-
What is the market cap of IMNM currently?
-
The market value of IMNM currently stands at $2.19B with its latest stock price at $22.92